STOCKHOLM, Sweden, Sept. 6 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company today sponsored a cardiology symposium at the European Society of Cardiology (ESC) Conference that addressed the growing number of complex patient cases and the benefits seen across multiple clinical studies with drug-eluting coronary stents. Complex cases include cardiac patients with diabetes, multi-vessel disease, small vessels and hypertension.
Among the presentations, Professor Martin Rothman, Barts and the London NHS Trust Hospital, United Kingdom, reviewed an analysis of overlapping stent procedures from four randomized clinical studies. Approximately 25 percent of coronary stent procedures involve overlapping two or more stents in order to fully cover a lesion inside an artery.
The analysis examined the SIRIUS (SIRolImUS-coated Bx Velocity balloon- expandable stent in the treatment of patients with de novo coronary artery lesions), E-SIRIUS (European version of SIRIUS), DIRECT (DIRECT stenting using the Sirolimus-eluting Bx Velocity stent) and SVELTE (Study in Patients with De Novo Coronary Artery Lesions in Small Vessels Treated with the CYPHER(R) Stent) trials. The overall conclusion of this analysis suggests there is a significant difference with the CYPHER(R) Stent vs. bare metal stents in overlapping stent cases.
Specifically, the analysis showed that overlapping CYPHER(R) Stents resulted in a lower overall major adverse cardiac event (MACE) than the bare metal control arm. The MACE rate was identified as death (all-cause mortality), heart attacks (myocardial infarction), repeat procedures (target lesion revascularization) and non Q-wave heart attack rate at one year post procedure.
The analysis showed patients who received overlapping CYPHER(R) Stents had a significantly lower incidence of MACE and non Q-wave myocardial infarctions (heart attacks) than the patients treated in the bare metal control arm at one year (7.4 percent versus 31.5 percent; p<0.001), (1.5 percent versus 4.6 percent; p=0.03) respectively.
"The number of patients with complex lesions is leading to an increased interest in overlapping stent data among cardiologists," said Professor Martin Rothman, Barts and the London NHS Trust Hospital, United Kingdom. "The results of this analysis once again underscore the safety of the CYPHER(R) Stent in treating complex cases."
Other session topics and speakers at the symposium included: -- Treatment Options for Diabetic Patients Speaker: Dr. Christian Spaulding, Cochin Hospital, René Descartes University, Paris, France -- Treatment Options for Multi Vessel Disease Speaker: Dr. Patrick Serruys, Cardiac Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, Netherlands -- Lesion Complexity Determines Clinical Outcome Speaker: Dr. Chaim Lotan, Director, Department of Cardiology, Hadassah University Medical Center, Jerusalem About the CYPHER(R) Stent
The CYPHER(R) Stent continues to break new ground in fighting one of the most formidable challenges in the treatment of heart disease: restenosis or the re-narrowing of a coronary artery after stenting. Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in 80 countries and has been used by doctors to treat more than one million patients worldwide. With more than 40 clinical trials conducted or in progress worldwide, the CYPHER(R) Stent remains the most studied drug-eluting stent today.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
* Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth Pharmaceuticals.
Cordis CorporationCONTACT: Terri Mueller, Cordis Corporation, Office: +1-786-313-8687, Cell:+1-305-903-9980, tmueller@crdus.jnj.com; Todd Ringler, Edelman, Office:+1-212-704-4572, Cell: +1-617-872-1235, todd.ringler@edelman.com
Web site: http://www.cordis.com/